HIV/AIDS Topics 4. PrEP Use Widens, But Disparities Remain
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
Pre-exposure prophylaxis (PrEP) was again a major HIV story in 2016. The latest figures from a pharmacy survey by Gilead Sciences showed that more than 79,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for HIV prevention, but the survey does not include all PrEP providers and most experts think this estimate is low.
5. HIV Prevention for Women
- Details
- Category: HIV Sexual Transmission
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
Use of Truvada for pre-exposure prophylaxis (PrEP) is highly effective and is now widely used among gay men, but biomedical HIV prevention for women has lagged behind.
Combination HIV Vaccine Efficacy Trial Launches in South Africa
- Details
- Category: HIV Vaccines
- Published on Wednesday, 30 November 2016 00:00
- Written by NIAID
A new HIV vaccine efficacy study -- the first in 7 years -- got underway this week in Cape Town, South Africa. The HVTN 702 trial will evaluate the safety and effectiveness of 2 experimental vaccines -- ALVAC-HIV and a gp120 protein subunit vaccine -- related to a combination that previously demonstrated modest efficacy in the RV144 trial in Thailand. The study aims to enroll more than 5400 sexually active adults and results are expected in late 2020.
Syringe Service Use Up, But a Third of People Who Inject Drugs Still Share Needles
- Details
- Category: Injection Drug Use
- Published on Wednesday, 30 November 2016 00:00
- Written by Liz Highleyman
Use of syringe exchange and distribution services has increased substantially over the past decade, and HIV diagnoses among people who inject drugs have fallen by nearly half, but just a quarter of drug injectors use only sterile needles and a third reported sharing a needle within the past year, according to the latest Vital Signs report from the Centers for Disease Control and Prevention.
HIVR4P 2016: The Long Tail Problem -- Injectable PrEP Trial To Be Extended Due to Drug Persistence
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Monday, 14 November 2016 00:00
- Written by Gus Cairns
A study presented at last month’s HIV Research for Prevention (HIVR4P) conference in Chicago shows that in a minority of people who were given the experimental injectable drug cabotegravir as HIV pre-exposure prophylaxis (PrEP), the drug was still measurable in their body a full year after their last injection.
Web Design and Development by